Tagged with Gilead

Global Gilead Sciences’ Jacopo Andreose PhD is a 20+ year pharma veteran and is today responsible for setting company strategy, planning and execution for over 150 countries across Asia, Russia/CIS, Latin and Central America, the Middle East, and Africa. In an exclusive conversation, Andreose outlines how Gilead was able to roll…

Turkey After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for its HIV and oncology treatments, announced a USD 60 million investment in Turkey, partnering with local player Pharmactive to produce…

MEA The Middle East and Africa, combined, represent the world’s fifth largest regional pharma market. According to IQVIA’s recent figures, most of the largest markets grew, although slowly due to COVID lockdowns, with Saudi Arabia in the top position. Multinational companies continue to “dominate” the region with Gilead Sciences experiencing huge…

Italy Italy is a key destination for global clinical trial programs with EUR 700 million invested in 2020 alone according to national industry association Farmindustria, bringing access to medicines, knowledge, skills, and economic benefits. Here, Italy country managers from some of the world’s leading pharma companies weigh in on the pros…

Global Less than two months passed between the WHO’s official pandemic declaration and remdesivir’s emergency use authorisation in the United States in May 2020. Today, the intravenous antiviral, sold by Gilead Sciences under the brand name Veklury, has generated over USD 8 billion in sales.   Remdesivir’s success as a treatment…

USA Pfizer and MSD recently became the latest companies to have COVID-19 treatments authorised by either the US FDA or EMA. Their oral antiviral drugs joined several monoclonal antibodies and others on the list of options available to patients in Europe and the United States. Here is an updated list of…

Italy Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in the early studies of remdesivir as a treatment against severe COVID-19 disease; how Gilead is working to eliminate viral Hepatitis…

MEA The top 10 fastest growing pharma companies in the Middle East and Africa (region) ranked by previous period growth between MAT Q2 2020 and MAT Q2 2021. The list is dominated by regional players including Julphar, Sedico/Acdima and Eva Pharma, but multinational firms are also represented by Gilead Sciences, Takeda,…

Saudi Arabia Frederico Silva outlines the highlights of his two years heading up Gilead Sciences’ relatively young Middle-East affiliate, how Gilead has pivoted to serve evolving healthcare needs during the COVID-19 pandemic, and its commitment to inter-stakeholder collaboration in increasingly important markets such as Saudi Arabia.   The Saudi FDA and other…

China A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene therapy space, as multinationals look to bring their new therapies to the rapidly expanding China market   Yescarta, originally approved in the US in 2017…

Ireland The Top 10 pharma companies in Ireland, ranked by annual turnover in The Irish Times Top 1000 list for 2021. Dublin-headquartered Allergan tops the list, followed by global giants MSD, Pfizer, and Gilead. Made with Visme Infographic Maker

Gilead With remdesivir practically a household name today as the first therapeutic to be approved for the treatment of COVID-19 patients, Gilead chairman and CEO Daniel O’Day and Gilead vice-president and general manager of the Asia 5 region (Singapore, South Korea, Hong Kong, Taiwan, Malaysia) Andrew Hexter are determined to stress…